Page last updated: 2024-12-07
ucn 1028 a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
calphostin A: structure given in first source; isolated from Cladosporium cladosporioides [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 129153 |
MeSH ID | M0163701 |
Synonyms (9)
Synonym |
---|
calphostin a |
1-[12-(2-benzoyloxypropyl)-3,10-dihydroxy-2,6,7,11-tetramethoxy-4,9-dioxoperylen-1-yl]propan-2-yl benzoate |
3,10-perylenedione, 1,12-bis(2-(benzoyloxy)propyl)-4,9-dihydroxy-2,6,7,11-tetramethoxy- |
ucn 1028 a |
120461-92-9 |
ucn 1028a |
ucn-1028a |
DTXSID20923404 |
(3,10-dihydroxy-2,6,7,11-tetramethoxy-4,9-dioxo-4,9-dihydroperylene-1,12-diyl)di(propane-1,2-diyl) dibenzoate |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" These toxic effects did not occur in the dark or after preincubation with the antioxidant alpha-tocopherol." | ( Membrane toxicity of the protein kinase C inhibitor calphostin A by a free-radical mechanism. Mathes, C; Thompson, SH; Wang, SS, 1993) | 0.29 |
" These toxic effects did not occur in the dark or after preincubation with the antioxidant alpha-tocopherol." | ( Membrane toxicity of the protein kinase C inhibitor calphostin A by a free-radical mechanism. Mathes, C; Thompson, SH; Wang, SS, 1993) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (50.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |